1.70
-0.08(-4.49%)
Currency In USD
Address
855 N Wolfe Street
Baltimore, FL 21205
United States of America
Phone
(737)-289-0835
Website
Sector
Healthcare
Industry
Biotechnology
Employees
1
First IPO Date
April 09, 2019
| Name | Title | Pay | Year Born |
| Mr. Erez Aminov | Chairman of the Board & Chief Executive Officer | 277,550 | 1979 |
| Ms. Michelle Yanez M.B.A. | Chief Financial Officer, Treasurer & Secretary | 147,833 | 1973 |
| Dr. Itzchak Angel Ph.D. | Chief Scientific Advisor | 0 | N/A |
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.